Tacrolimus dose requirement in pediatric liver transplantation: Influence of CYP3A5 gene polymorphism

Pharmacogenomics

Volumn 14, Issue 9, 2013, Pages 1017-1025

  Durand, Philippe ^a   Debray, Dominique ^a   Kolaci, Mikaela ^b   Bouligand, Jerome ^b   Furlan, Valérie ^a   Fabre, Monique ^a,c   Letierce, Alexia ^a   Verstuyft, Céline ^b   Becquemont, Laurent ^a,b  

^a BICÊTRE HOSPITAL   (France)

^b UNIVERSITÉ PARIS SACLAY   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

CYP3A5; Pediatric liver transplantation; Pharmacogenetics; Tacrolimus

Indexed keywords

CYTOCHROME P450 3A5; FLUCONAZOLE; TACROLIMUS;

ACUTE GRAFT REJECTION; ADOLESCENT; ARTICLE; CHILD; CYP3A5 GENE; DNA POLYMORPHISM; DRUG BLOOD LEVEL; DRUG DOSE REGIMEN; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC ANALYSIS; GENOTYPE; GRAFT RECIPIENT; HUMAN; LIVER GRAFT REJECTION; LIVER HISTOLOGY; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRESCRIPTION; RETROSPECTIVE STUDY; STEADY STATE;

ALLELES; CHILD; CHILD, PRESCHOOL; CYTOCHROME P-450 CYP3A; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; GENE EXPRESSION; GENOTYPE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER TRANSPLANTATION; MALE; POLYMORPHISM, GENETIC; RETROSPECTIVE STUDIES; TACROLIMUS; TISSUE DONORS;

EID: 84880468805     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.13.87     Document Type: Article

References (29)

1. Fouquet V, Alves A, Branchereau S et al. Long-term outcome of pediatric liver transplantation for biliary atresia: A 10 year follow-up in a single center. Liver Transpl. 11(2), 152-160 (2005).
2. Kelly D. Safety and efficacy of tacrolimus in pediatric liver recipients. Pediatr. Transplant. 15(1), 19-24 (2010).
3. Kelly D, Jara P, Rodeck B et al. Tacrolimus and steroids versus ciclosporin microemulsion, steroids, and azathioprine in children undergoing liver transplantation: Randomised European multicentre trial. Lancet 364(9439), 1054-1061 (2004).
4. Anglicheau D, Verstuyft C, Laurent-Puig P et al. Association of the multidrug resistance-1 gene single-nucleotide polymorphisms with the tacrolimus dose requirements in renal transplant recipients. J. Am. Soc. Nephrol. 14(7), 1889-1896 (2003).
5. Fukudo M, Yano S, Masuda S et al. Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin. Pharmacol. Ther. 80, 331-345 (2006).
6. Zheng H, Webber S, Zeevi A et al. Tacrolimus dosing in pediatric heart transplant patients is related to CYP3A5 and MDR1 gene polymorphisms. Am. J. Transplant. 3(4), 477-483 (2003).
7. Zhao W, Elie V, Roussey G et al. Population pharmacokinetics and pharmacogenetics of tacrolimus in de novo pediatric kidney transplant recipients. Clin. Pharmacol. Ther. 86(6), 609-618 (2009).
8. Goto M, Masuda S, Kiuchi T et al. CYP3A5*1-carrying graft liver reduces the concentration/oral dose ratio of tacrolimus in recipients of living-donor liver transplantation. Pharmacogenetics 14(7), 471-478 (2004).
9. Wei-Lin W, Jing J, Shu-Sen Z et al. Tacrolimus dose requirement in relation to donor and recipient ABCB1 and CYP3A5 gene polymorphisms in chinese liver transplant patients. Liver Transpl. 12, 775-780 (2006).
10. Masuda S, Goto M, Fukatsu S et al. Intestinal MDR1/ABCB1 level at surgery as a risk factor of acute cellular rejection in living-donor liver transplant patients. Clin. Pharmacol. Ther. 79, 90-102 (2006).
11. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat. Genet. 27(4), 383-391 (2001).
12. Thervet E, Loriot MA, Barbier S et al. Optimization of initial tacrolimus dose using pharmacogenetic testing. Clin. Pharmacol. Ther. 87(6), 721-726 (2010).
13. Quteineh L, Verstuyft C. Pharmacogenetics in immunosuppressants: Impact on dose requirement of calcineurin inhibitors in renal and liver pediatric transplant recipients. Curr. Opin. Organ. Transplant. 15, 601-607 (2010).
14. Quteineh L, Verstuyft C, Furlan V et al. Influence of CYP3A5 genetic polymorphism on tacrolimus daily dose requirements and acute rejection in renal graft recipients. Basic Clin. Pharmacol. Toxicol. 103(6), 546-552 (2008).
15. Briceño J, Ciria R, Pleguezuelo M et al. Impact of donor graft steatosis on overall outcome and viral recurrence after liver transplantation for hepatitis C virus cirrhosis. Liver Transpl. 15, 37-48 (2009).
16. Koçbiyik A, Demirhan B, Sevmis S, Budakoglu I, Karakayali H, Haberal M. Role of postreperfusion subcapsular wedge biopsies in predicting initially poor graft function after liver transplantation. Transplant. Proc. 41, 2747-2748 (2009
17. Busquets J, Figueras J, Serrano T et al. Postreperfusion biopsies are useful in predicting complications after liver transplantation. Liver Transpl. 7, 432-435 (2001).
18. Kakizoe S, Yanaga K, Starzl T, Demetris A. Evaluation of protocol before transplantation and after reperfusion biopsies from human orthotopic liver allografts: Considerations of preservation and early immunological injury. Hepatology 11, 932-941 (1990).
19. Ferraris J, Argibay P, Costa L et al. Influence of CYP3A5 polymorphism on tacrolimus maintenance doses and serum levels after renal transplantation: Age dependency and pharmacological interaction with steroids. Pediatr. Transplant. 15, 525-532 (2011).
20. Gijsen V, Mital S, van Schaik RH et al. Age and CYP3A5 genotype affect tacrolimus dosing requirements after transplant in pediatric heart recipients. J. Heart Lung Transplant. 30(12), 1352-1359 (2011).
21. Kuypers DR, de Jonge H, Naesens M, Lerut E, Verbeke K, Vanrenterghem Y. CYP3A5 and CYP3A4 but not MDR1 single-nucleotide polymorphisms determine long-term tacrolimus disposition and drug-related nephrotoxicity in renal recipients. Clin. Pharmacol. Ther. 82(6), 711-725 (2007).
22. de Wildt SN, van Schaik RH, Soldin OP et al. The interactions of age, genetics, and disease severity on tacrolimus dosing requirements after pediatric kidney and liver transplantation. Eur. J. Clin. Pharmacol. 67(12), 1231-1241 (2011).
23. Yu S, Wu L, Jin J et al. Influence of CYP3A5 gene polymorphisms of donor rather than recipient to tacrolimus individual dose requirement in liver transplantation. Transplantation 81(1), 46-51 (2006).
24. Ji E, Choi L, Suh KS, Cho JY, Han N, Oh JM. Combinational effect of intestinal and hepatic CYP3A5 genotypes on tacrolimus pharmacokinetics in recipients of living donor liver transplantation. Transplantation 94(8), 866-872 (2012).
25. Naesens M, Salvatierra O, Li L, Kambham N, Concepcion W, Sarwal M. Maturation of dose-corrected tacrolimus predose trough levels in pediatric kidney allograft recipients. Transplantation 85(8), 1139-1145 (2008).
26. Fakhoury M, Litalien C, Medard Y et al. Localization and mRNA expression of CYP3A and P-glycoprotein in human duodenum as a function of age. Drug Metab. Dispos. 33(11), 1603-1607 (2005).
27. Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349(12), 1157-1167 (2003).
28. Kuypers DR, de Jonge H, Naesens M, Vanrenterghem Y. Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients. Pharmacogenet. Genomics 18(10), 861-868 (2008).
29. Gibbs MA, Thummel KE, Shen DD, Kunze KL. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: Comparison of ki values and impact of CYP3A5 expression. Drug Metab. Dispos. 27(2), 180-187 (1999).